Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


20.03.2017

4 Am J Hematol
2 Ann Hematol
2 Blood
1 BMC Cancer
1 BMC Genomics
1 Cancer
2 Cancer Chemother Pharmacol
1 Eur J Haematol
1 Eur J Immunol
4 Int J Hematol
5 J Clin Oncol
1 J Pediatr Hematol Oncol
14 Leuk Lymphoma
3 Leuk Res
2 Leukemia
2 N Engl J Med
1 Oncogene
3 Oncol Rep
3 PLoS One
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Am J Hematol. 2017 Mar 17. doi: 10.1002/ajh.24722.
    PubMed     Text format     Abstract available

  2. MAURO FR, Galieni P, Tedeschi A, Laurenti L, et al
    Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24714.
    PubMed     Text format     Abstract available

  3. MICHALLET AS, Campidelli A, Lequeu H, Dilhuydy MS, et al
    Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24715.
    PubMed     Text format    

  4. SHORT NJ, Kantarjian HM, Ko H, Khoury JD, et al
    Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
    Am J Hematol. 2017 Mar 15. doi: 10.1002/ajh.24720.
    PubMed     Text format    


    Ann Hematol

  5. MO XD, Zhang XH, Xu LP, Wang Y, et al
    Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2017 Mar 11. doi: 10.1007/s00277-017-2960.
    PubMed     Text format     Abstract available

  6. BRECCIA M, Pregno P, Spallarossa P, Arboscello E, et al
    Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
    Ann Hematol. 2017;96:549-558.
    PubMed     Text format     Abstract available


    Blood

  7. HEIN N, Cameron DP, Hannan KM, Nguyen NN, et al
    Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
    Blood. 2017 Mar 10. pii: blood-2016-05-718171. doi: 10.1182/blood-2016-05-718171
    PubMed     Text format     Abstract available

  8. LOGHAVI S, Khoury JD
    Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence.
    Blood. 2017;129:1563.
    PubMed     Text format    


    BMC Cancer

  9. NABHAN C, Mato A, Flowers CR, Grinblatt DL, et al
    Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
    BMC Cancer. 2017;17:198.
    PubMed     Text format     Abstract available


    BMC Genomics

  10. HUANG D, Ovcharenko I
    Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia.
    BMC Genomics. 2017;18:236.
    PubMed     Text format     Abstract available


    Cancer

  11. BORTHAKUR G, Popplewell L, Boyiadzis M, Foran J, et al
    Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Cancer. 2016;122:1871-9.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  12. GALEOTTI L, Ceccherini F, Domingo D, Laurino M, et al
    Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3271.
    PubMed     Text format     Abstract available

  13. BEN HASSINE I, Gharbi H, Soltani I, Teber M, et al
    hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Mar 12. doi: 10.1007/s00280-017-3266.
    PubMed     Text format     Abstract available


    Eur J Haematol

  14. TAGHILOO S, Allahmoradi E, Tehrani M, Hossein-Nataj H, et al
    Frequency and functional characterization of Exhausted CD8+ T-cells in chronic lymphocytic leukemia.
    Eur J Haematol. 2017 Mar 17. doi: 10.1111/ejh.12880.
    PubMed     Text format     Abstract available


    Eur J Immunol

  15. FIDANZA M, Seif AE, Jo S, Kariminia A, et al
    IFN-gamma directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life.
    Eur J Immunol. 2017 Mar 15. doi: 10.1002/eji.201646806.
    PubMed     Text format     Abstract available


    Int J Hematol

  16. DAVILA ML, Sadelain M
    Biology and clinical application of CAR T cells for B cell malignancies.
    Int J Hematol. 2016;104:6-17.
    PubMed     Text format     Abstract available

  17. BADAT M, Oyesanya F, Cervi P
    CLL with intra-cytoplasmic lymphocytic inclusion bodies.
    Int J Hematol. 2016;104:411-2.
    PubMed     Text format    

  18. HASSAN IB, Zaabi MR, Alam A, Hashim MJ, et al
    Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).
    Int J Hematol. 2017 Mar 14. doi: 10.1007/s12185-017-2211.
    PubMed     Text format     Abstract available

  19. ISHIHARA T, Nogami K, Matsumoto T, Nomura A, et al
    Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.
    Int J Hematol. 2017 Mar 16. doi: 10.1007/s12185-017-2213.
    PubMed     Text format     Abstract available


    J Clin Oncol

  20. IACOBUCCI I, Mullighan CG
    Genetic Basis of Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2017;35:975-983.
    PubMed     Text format     Abstract available

  21. TIACCI E, Pettirossi V, Schiavoni G, Falini B, et al
    Genomics of Hairy Cell Leukemia.
    J Clin Oncol. 2017;35:1002-1010.
    PubMed     Text format     Abstract available

  22. BULLINGER L, Dohner K, Dohner H
    Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
    J Clin Oncol. 2017;35:934-946.
    PubMed     Text format     Abstract available

  23. LAZARIAN G, Guieze R, Wu CJ
    Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017;35:984-993.
    PubMed     Text format     Abstract available

  24. LENZ G
    Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017 Mar 14:JCO2016720102. doi: 10.1200/JCO.2016.72.0102.
    PubMed     Text format    


    J Pediatr Hematol Oncol

  25. BEN MAHMOUD L, Mdhaffar M, Ghozzi H, Ammar M, et al
    Oxidative Stress in Tunisian Patients With Acute Lymphoblastic Leukemia and Its Involvement in Leukemic Relapse.
    J Pediatr Hematol Oncol. 2017 Mar 16. doi: 10.1097/MPH.0000000000000793.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  26. DARAKI A, Zachaki S, Rosmaraki F, Kalomoiraki M, et al
    Association of GSTP1 inactivating polymorphism with acute myeloid leukemia and its specific chromosomal abnormalities.
    Leuk Lymphoma. 2017 Mar 2:1-3. doi: 10.1080/10428194.2017.1295148.
    PubMed     Text format    

  27. KO DR, Jang JE, Chung SP, Lee JW, et al
    Usefulness of the delta neutrophil index as an ancillary test in the emergency department for the early diagnosis of suspected acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Mar 2:1-8. doi: 10.1080/10428194.2017.1296142.
    PubMed     Text format     Abstract available

  28. ISKIERKA-JAZDZEWSKA E, Hus M, Giannopoulos K, Madro E, et al
    Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1292353.
    PubMed     Text format    

  29. VILIA MG, Fonte E, Veliz Rodriguez T, Tocchetti M, et al
    The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-7. doi: 10.1080/10428194.2017.1295142.
    PubMed     Text format     Abstract available

  30. ESKAZAN AE
    Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 28:1-2. doi: 10.1080/10428194.2017.1295145.
    PubMed     Text format    

  31. OKA S, Ono K, Nohgawa M
    Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Leuk Lymphoma. 2017 Feb 28:1-3. doi: 10.1080/10428194.2017.1295146.
    PubMed     Text format    

  32. KHAN N, Hantel A, Knoebel RW, Artz A, et al
    Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-7. doi: 10.1080/10428194.2017.1289524.
    PubMed     Text format     Abstract available

  33. ORGEL E, Mueske NM, Sposto R, Gilsanz V, et al
    A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Feb 20:1-9. doi: 10.1080/10428194.2017.1289526.
    PubMed     Text format     Abstract available

  34. THOMAS JS, Jagasia M, Vnencak-Jones CL
    Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Feb 14:1-4. doi: 10.1080/10428194.2017.1287362.
    PubMed     Text format    

  35. XIA D, Zhang YT, Xu GP, Yan WW, et al
    Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells.
    Leuk Lymphoma. 2017 Feb 13:1-10. doi: 10.1080/10428194.2017.1287358.
    PubMed     Text format     Abstract available

  36. MAITI A, Cortes J, Ferrajoli A, Estrov Z, et al
    Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Feb 9:1-6. doi: 10.1080/10428194.2017.1283030.
    PubMed     Text format    

  37. MU Q, Guo L, Hu Y, Sheng L, et al
    SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
    Leuk Lymphoma. 2017 Feb 9:1-3. doi: 10.1080/10428194.2017.1287357.
    PubMed     Text format    

  38. VOJDEMAN FJ, Herman SE, Kirkby N, Wiestner A, et al
    Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Feb 7:1-7. doi: 10.1080/10428194.2017.1285027.
    PubMed     Text format     Abstract available

  39. REBECHI MT, Pratz KW
    Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.
    Leuk Lymphoma. 2017 Feb 6:1-11. doi: 10.1080/10428194.2017.1283031.
    PubMed     Text format     Abstract available


    Leuk Res

  40. MAURO FR, Morabito F, Vincelli ID, Petrucci L, et al
    Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.
    Leuk Res. 2017;57:65-71.
    PubMed     Text format     Abstract available

  41. GRANADOS-RIVERON JT, Aquino-Jarquin G
    Reversal of multidrug resistance of leukemia cells is not necessarily induced by direct miR-138/MDR1 promoter interaction.
    Leuk Res. 2017;57:55-56.
    PubMed     Text format    

  42. HU Y, Dong X, Chu G, Lai G, et al
    miR-137 downregulates c-kit expression in acute myeloid leukemia.
    Leuk Res. 2017;57:72-77.
    PubMed     Text format     Abstract available


    Leukemia

  43. POULAIN L, Sujobert P, Zylbersztejn F, Barreau S, et al
    High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  44. YUAN T, Yang Y, Chen J, Li W, et al
    Regulation of PI3K signaling in T cell acute lymphoblastic leukemia: A novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  45. KHAN U, Hadid T
    Plasmacytomas and Plasma-Cell Leukemia.
    N Engl J Med. 2017;376:e19.
    PubMed     Text format    

  46. LONGO DL
    Imatinib Changed Everything.
    N Engl J Med. 2017;376:982-983.
    PubMed     Text format    


    Oncogene

  47. FERREIRA HJ, Heyn H, Vizoso M, Moutinho C, et al
    DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format    


    Oncol Rep

  48. CHEN Y, Liu ZH, Xia J, Li XP, et al
    20(S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/beta-catenin signaling pathway.
    Oncol Rep. 2016;36:137-46.
    PubMed     Text format     Abstract available

  49. HAN MH, Lee WS, Nagappan A, Kim HJ, et al
    Polyphenols from Korean prostrate spurge Euphorbia supina induce apoptosis through the Fas-associated extrinsic pathway and activation of ERK in human leukemic U937 cells.
    Oncol Rep. 2016;36:99-107.
    PubMed     Text format     Abstract available

  50. PAN GZ, Zhai FX, Lu Y, Fang ZG, et al
    RUNX3 plays an important role in As2O3induced apoptosis and allows cells to overcome MSCmediated drug resistance.
    Oncol Rep. 2016;36:1927-38.
    PubMed     Text format     Abstract available


    PLoS One

  51. CHEN Y, Fang F, Hu Y, Liu Q, et al
    The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    PLoS One. 2016;11:e0154183.
    PubMed     Text format     Abstract available

  52. RAUZAN M, Chuah CT, Ko TK, Ong ST, et al
    The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
    PLoS One. 2017;12:e0174107.
    PubMed     Text format     Abstract available

  53. SALZBERG AC, Harris-Becker A, Popova EY, Keasey N, et al
    Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.
    PLoS One. 2017;12:e0173723.
    PubMed     Text format     Abstract available


    Virology

  54. BOI S, Dis EV, Hansen EJ, Rosenke K, et al
    Latent murine leukemia virus infection characterized by the release of non-infectious virions.
    Virology. 2017;506:19-27.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: